Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 101 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Pipeline Review, H2 2016', provides in depth analysis on Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted pipeline therapeutics. 

The report provides comprehensive information on the Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) 
- The report reviews Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) Overview 10
Therapeutics Development 11
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Products under Development by Stage of Development 11
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Products under Development by Therapy Area 12
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Products under Development by Indication 13
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Pipeline Products Glance 15
Late Stage Products 15
Early Stage Products 16
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Products under Development by Companies 17
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Products under Development by Universities/Institutes 22
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Therapeutics Assessment 24
Assessment by Monotherapy/Combination Products 24
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Companies Involved in Therapeutics Development 30
AbbVie Inc 30
Advinus Therapeutics Ltd 31
Arrien Pharmaceuticals, LLC 32
Aurigene Discovery Technologies Limited 33
Beijing Hanmi Pharmaceutical Co., Ltd. 34
Biogen Inc 35
Brickell Biotech, Inc. 36
Bristol-Myers Squibb Company 37
Celgene Corporation 38
Eli Lilly and Company 39
Genentech, Inc. 40
Genfit SA 41
GlaxoSmithKline Plc 42
Japan Tobacco Inc. 43
Lead Pharma Holding B.V. 44
Nuevolution AB 45
Pfizer Inc. 46
Phenex Pharmaceuticals AG 47
Reata Pharmaceuticals, Inc. 48
Takeda Pharmaceutical Company Limited 49
Teijin Pharma Limited 50
Visionary Pharmaceuticals, Inc. 51
Vitae Pharmaceuticals, Inc. 52
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Drug Profiles 53
ABBV-553 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
ARN-6039 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
BBI-6000 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Drug to Antagonize ROR-Gamma for Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
GSK-2981278 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
INV-17 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
JTE-451 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
Small Molecule to Agonize ROR-Gamma for Inflammation, Respiratory and Oncology - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
Small Molecule to Antagonize RAR-Related Orphan Receptor Gamma for Psoriasis - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
Small Molecule to Antagonize ROR-Gamma for Multiple Sclerosis - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
Small Molecule to Target ROR Gamma for Autoimmune Disorders - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
Small Molecules to Agonize RAR-Related Orphan Receptor Gamma for Inflammatory Bowel Disease - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
Small Molecules to Agonize ROR gamma for Breast Cancer - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
Small Molecules to Agonize ROR-Gamma for Autoimmune Disease - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
Small Molecules to Agonize ROR-Gamma for Oncology - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
Small Molecules to Antagonize ROR-Gamma for Autoimmune Disorders - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
Small Molecules to Antagonize ROR-Gamma T for Rheumatoid Arthritis and Psoriasis - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
Small Molecules to Antagonize RORc for Autoimmune Diseases and Inflammation - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
Small Molecules to Antagonize RORC for Immunology, Multiple Sclerosis and Non-Alcoholic Steatohepatitis - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
Small Molecules to Antagonize RORC for Immunology, Multiple Sclerosis, Non-Alcoholic Steatohepatitis - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
Small Molecules to Inhibit ROR gamma-t for Autoimmune Diseases - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
Small Molecules to Inhibit ROR gamma-t for Multiple Sclerosis and Rheumatoid Arthritis - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
Small Molecules to Inhibit ROR-Gamma for Inflammation - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
Small Molecules to Inhibit ROR-Gamma T for Autoimmune Disorders and Inflammation - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
Small Molecules to Target ROR gamma for Autoimmune Diseases - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
SR-1001 - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
SR-2211 - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
TAK-828 - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
TGFTX-1 - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
TMP-778 - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
VPR-66 - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
VTP-43742 - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
VTP-45489 - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Dormant Projects 89
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Discontinued Products 90
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Featured News & Press Releases 91
Jun 06, 2016: Vitae Pharmaceuticals Announces Appointment of Carole Sable, M.D., as Chief Medical Officer 91
Jun 03, 2016: Arrien Pharmaceuticals Initiated Phase I Clinical Trials of ARN-6039 as a New Agent for Treatment of Multiple Sclerosis 91
May 09, 2016: Arrien Pharmaceuticals to Initiate the Phase I Clinical trials of Autoimmune Drug 92
Apr 29, 2016: Arrien Pharmaceuticals Announces FDA Accepts IND Application For ARN-6039 92
Mar 16, 2016: Vitae Pharmaceuticals Achieves Proof-of-Concept with First-in-Class RORyt Inhibitor in Moderate to Severe Psoriasis 93
Nov 18, 2015: Vitae Pharmaceuticals Announces Positive Top-Line Results From a Phase 1 Multiple Ascending Dose Trial of VTP-43742 93
Nov 03, 2015: Lycera Announces Progress in Immuno-Oncology Program to be Presented at Society for Immunotherapy of Cancer (SITC) 2015 Annual Meeting 94
Nov 02, 2015: Lead Pharma Achieves first Milestone for Developmen t of Autoimmune Diseases Treatments in Research Collabor ation with Sanofi 95
Sep 29, 2015: Vitae Pharmaceuticals Initiates Second Part of a Phase 1 Multiple Ascending Dose Study of VTP-43742 in Psoriatic Patients 96
Sep 08, 2015: Vitae Pharmaceuticals Announces Positive Top-Line Results From Initial Phase 1 Study of First-in-Class RORyt Inhibitor VTP-43742 in Autoimmune Disorders 96
Aug 10, 2015: Vitae Pharmaceuticals Announces Initiation of a Phase 1 Multiple Ascending Dose Study of VTP-43742 in Autoimmune Disorders 97
Aug 05, 2015: Aurigene to Present its RORg Inverse Agonist Program at World Congress on Inflammation, 2015 97
Jun 29, 2015: Vitae Pharmaceuticals Announces Initiation of a Phase 1 Single Ascending Dose Study of VTP-43742 in Autoimmune Disorders 98
Apr 16, 2015: Vitae Pharmaceuticals to Present at Keystone Symposia on Mechanisms of Pro-Inflammatory Diseases 98
Mar 17, 2015: New Compound Prevents Type 1 Diabetes in Animal Models—Before It Begins 99
Appendix 100
Methodology 100
Coverage 100
Secondary Research 100
Primary Research 100
Expert Panel Validation 100
Contact Us 100
Disclaimer 101

List of Tables

Number of Products under Development for, H2 2016 11
Number of Products under Development by Therapy Area, H2 2016 12
Number of Products under Development by Indication, H2 2016 14
Comparative Analysis by Late Stage Development, H2 2016 15
Comparative Analysis by Early Stage Products, H2 2016 16
Number of Products under Development by Companies, H2 2016 17
Products under Development by Companies, H2 2016 18
Products under Development by Companies, H2 2016 (Contd..1) 19
Products under Development by Companies, H2 2016 (Contd..2) 20
Products under Development by Companies, H2 2016 (Contd..3) 21
Number of Products under Investigation by Universities/Institutes, H2 2016 22
Products under Investigation by Universities/Institutes, H2 2016 23
Assessment by Monotherapy/Combination Products, H2 2016 24
Number of Products by Stage and Mechanism of Action, H2 2016 26
Number of Products by Stage and Route of Administration, H2 2016 28
Number of Products by Stage and Molecule Type, H2 2016 29
Pipeline by AbbVie Inc, H2 2016 30
Pipeline by Advinus Therapeutics Ltd, H2 2016 31
Pipeline by Arrien Pharmaceuticals, LLC, H2 2016 32
Pipeline by Aurigene Discovery Technologies Limited, H2 2016 33
Pipeline by Beijing Hanmi Pharmaceutical Co., Ltd., H2 2016 34
Pipeline by Biogen Inc, H2 2016 35
Pipeline by Brickell Biotech, Inc., H2 2016 36
Pipeline by Bristol-Myers Squibb Company, H2 2016 37
Pipeline by Celgene Corporation, H2 2016 38
Pipeline by Eli Lilly and Company, H2 2016 39
Pipeline by Genentech, Inc., H2 2016 40
Pipeline by Genfit SA, H2 2016 41
Pipeline by GlaxoSmithKline Plc, H2 2016 42
Pipeline by Japan Tobacco Inc., H2 2016 43
Pipeline by Lead Pharma Holding B.V., H2 2016 44
Pipeline by Nuevolution AB, H2 2016 45
Pipeline by Pfizer Inc., H2 2016 46
Pipeline by Phenex Pharmaceuticals AG, H2 2016 47
Pipeline by Reata Pharmaceuticals, Inc., H2 2016 48
Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 49
Pipeline by Teijin Pharma Limited, H2 2016 50
Pipeline by Visionary Pharmaceuticals, Inc., H2 2016 51
Pipeline by Vitae Pharmaceuticals, Inc., H2 2016 52
Dormant Projects, H2 2016 89
Discontinued Products, H2 2016 90